Skip to main content
OpenTrials
Completed

NCT Number: NCT03026218

Group and Mobile Care for Gestational Diabetes

A critical variation in the provision of prenatal care to women with GDM is the need to keep patients engaged with their care between visits by tracking glucose levels using finger sticks and making dietary and other lifestyle modifications to keep these levels at or close to normal. Multiple studies have demonstrated that the use of mobile devices can improve medical outcomes. In order to keep patients engaged between appointments and improve self-care/lifestyle, we will study the use of a glucose monitoring system with nutrition therapy called GlucoseMama(GM). GM is a mobile app on the iOS system that individuals with GDM will use to tract blood sugars and number of carbs consumed. In addition, it will give the user positive feedback and rewards for using the system. This model of group care with mobile phone monitoring and reminders for women with GDM has not been previously studied. A randomized control trial is purposed to determine if this approach improves patient care. The investigators hypothesize that group prenatal care along with inter-session mobile therapy will increase dietary compliance and therefore reduce the number of individuals requiring pharmacologic therapy and improve neonatal outcomes during pregnancy. Group prenatal care (GPC) will provide a community foundation to improve learning and increase the motivation of patients to learn and change. This motivation will be further strengthened by the use of the GlucoseMama monitoring system which will provide each patient with glucose tracking and individualized nutritional support.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–51 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of Maryland, Baltimore

Baltimore, Maryland, 21201, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Gestational Diabetes
  • Planning on delivering at home institution

Exclusion criteria

  • Unwilling to participate.

Treatment and study plan

GlucoseMama application with blood sugar monitoring and carb monitoring.

Other

We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.

Group prenatal care for GDM.

Other

group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.

Primary outcomes

  1. Reduction in the number of individuals requiring pharmacotherapy for treatment of gestational diabetes

    Time frame: 2 years

Secondary outcomes

  1. Reduction in the number of neonates born large for gestational age.

    Time frame: 2 years

  2. Increased number of individuals who are screened in the postpartum period for type 2 diabetes.

    Time frame: 2 years

  3. Reduction in the number of infants with neonatal hypoglycemia.

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

University of Maryland, Baltimore

Other

Registry information

Important dates

Study start
2017
Primary completion
2018
Study completion
2019
First posted
Jan 20, 2017
Registry last updated
Mar 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.